title: Phosphorylation of the myosin phosphatase targeting subunit and CPI-17 during Ca2+ sensitization in rabbit smooth muscle.
abstract: Myosin phosphatase (MLCP) plays a critical regulatory role in the Ca(2+) sensitivity of myosin phosphorylation and smooth muscle contraction. It has been suggested that phosphorylation at Thr(695) of the MLCP regulatory subunit (MYPT1) and at Thr(38) of the MLCP inhibitor protein CPI-17 results in inhibition of MLCP activity. We have previously demonstrated that CPI-17 Thr(38) phosphorylation plays an important role in G-protein-mediated inhibition of MLCP in tonic arterial smooth muscle. Here, we attempted to evaluate the function of MYPT1 in phasic rabbit portal vein (PV) and vas deferens (VD) smooth muscles. Using site- and phospho-specific antibodies, phosphorylation of MYPT1 Thr(695) and CPI-17 Thr(38) was examined along with MYPT1 Thr(850), which is a non-inhibitory Rho-kinase site. We found that both CPI-17 Thr(38) and MYPT1 Thr(850) were phosphorylated in response to agonists or GTPgammaS concurrently with contraction and myosin phosphorylation in alpha-toxin-permeabilized PV tissues. In contrast, phosphorylation of MYPT1 Thr(695) did not increase. Comparable results were also obtained in both permeabilized and intact VD. The Rho-kinase inhibitor Y-27632 and the protein kinase C (PKC) inhibitor GF109203X suppressed phosphorylation of MYPT1 Thr(850) and CPI-17 Thr(38), respectively, in intact VD while MYPT1 Thr(695) phosphorylation was insensitive to both inhibitors. These results indicate that phosphorylation of MYPT1 Thr(695) is independent of stimulation of G-proteins, Rho-kinase or PKC. In the phasic PV, phosphorylation of CPI-17 Thr(38) may contribute towards inhibition of MLCP while the phasic visceral VD, which has a low CPI-17 concentration, probably utilizes other Ca(2+) sensitizing mechanisms for inhibiting MLCP besides phosphorylation of MYPT1 and CPI-17.
authors.affiliation: Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC 20007, USA. kitazawa@bbri.org
authors.forename: Toshio
authors.initials: T
authors.lastname: Kitazawa
authors.forename: Masumi
authors.initials: M
authors.lastname: Eto
authors.forename: Terence P
authors.initials: TP
authors.lastname: Woodsome
authors.forename: Md
authors.initials: M
authors.lastname: Khalequzzaman
mesh_terms: D000577:Amides / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D004594:Electrophysiology; D019332:Endothelin-1 / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D008301:Maleimides / Q000494:pharmacology; D009124:Muscle Proteins / Q000378:metabolism*; D009130:Muscle, Smooth / Q000378:metabolism*; D009131:Muscle, Smooth, Vascular / Q000502:physiology; D018994:Myosin Light Chains / Q000378:metabolism; D043263:Myosin-Light-Chain Phosphatase; D010539:Permeability; D010656:Phenylephrine / Q000494:pharmacology; D010749:Phosphoprotein Phosphatases / Q000378:metabolism*; D010750:Phosphoproteins / Q000378:metabolism*; D010766:Phosphorylation; D011169:Portal Vein / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology; D011817:Rabbits; D010738:Type C Phospholipases / Q000494:pharmacology; D014649:Vas Deferens / Q000502:physiology; D014661:Vasoconstriction
chemical_list: D000577:Amides; C491521:CPI-17 protein, Oryctolagus cuniculus; D019332:Endothelin-1; D004791:Enzyme Inhibitors; D007211:Indoles; D007527:Isoenzymes; D008301:Maleimides; D009124:Muscle Proteins; D018994:Myosin Light Chains; D010750:Phosphoproteins; D011725:Pyridines; C108830:Y 27632; D010656:Phenylephrine; D010749:Phosphoprotein Phosphatases; D043263:Myosin-Light-Chain Phosphatase; D010738:Type C Phospholipases; C070515:bisindolylmaleimide I; D002118:Calcium